No General Purchase Limit on Lurbinectedin
Lurbinectedin (Zepzelca) has no universal federal or manufacturer-imposed limit on purchases for patients, pharmacies, or providers in the US. It's available by prescription for adults with metastatic small cell lung cancer after platinum chemotherapy, distributed through specialty pharmacies via the Zepzelca REMS program, which focuses on risk management rather than quantity caps.[1]
Why Might Purchases Feel Restricted?
Supply chain issues or high demand can create temporary shortages, as flagged by the FDA's drug shortage list—lurbinectedin appeared there intermittently in 2023 due to manufacturing delays, but resolved by early 2024.[2] Insurance prior authorizations or step therapy requirements often limit initial fills to specific doses (e.g., 3.2 mg/m² IV every 21 days), mimicking a "limit."[3]
Insurance and Coverage Caps
Most payers (Medicare, Medicaid, commercial plans) cover it without hard quantity limits, but copay caps or annual benefit maximums apply:
- Medicare Part D: No quantity limit, but coverage gaps or 5% coinsurance after catastrophic phase.
- Commercial: Plans like UnitedHealthcare or CVS Caremark may require quantity limits (e.g., 1 vial per 21 days) tied to treatment cycles.[4]
Patients can appeal denials or use Jazz Pharmaceuticals' patient assistance for uninsured/low-income cases, covering up to 100% costs without purchase caps.[5]
Pharmacy and Wholesale Rules
Retail/specialty pharmacies (e.g., Accredo, PANTHERx) dispense based on prescription—no DEA scheduling means no federal purchase quotas like opioids. Wholesalers track inventory but impose no public buy limits.[6]
International Availability and Limits
Outside the US, approvals vary:
| Country/Region | Status | Known Limits |
|---------------|--------|--------------|
| EU (as Zepzelca) | Approved 2021 | No purchase limits; national pricing controls |
| Canada | Not approved | N/A |
| Japan | Approved 2022 | Reimbursement caps per cycle |
| Australia | Under review | Potential PBS quantity restrictions if listed[7] |
Manufacturer Patents and Supply Outlook
Jazz Pharmaceuticals holds US patents until at least 2031 (composition of matter) and 2035 (methods of use), with no generic threats imminent per DrugPatentWatch.com.[8] No exclusivity limits purchases, but ongoing Phase 3 trials could boost demand.
[1]: Zepzelca REMS - https://zepzelca-rems.com
[2]: FDA Drug Shortages - https://www.fda.gov/drugs/drug-shortages
[3]: NCCN Guidelines SCLC v2.2024
[4]: JazzCares Support - https://www.jazzcares.com
[5]: JazzCares Patient Assistance - https://www.jazzpharma.com/patient-support
[6]: DEA Controlled Substances List (lurbinectedin unlisted)
[7]: EMA Approval Summary - https://www.ema.europa.eu
[8]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/ZEPZELCA